These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31026023)

  • 1. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.
    Grewal JK; Tessier-Cloutier B; Jones M; Gakkhar S; Ma Y; Moore R; Mungall AJ; Zhao Y; Taylor MD; Gelmon K; Lim H; Renouf D; Laskin J; Marra M; Yip S; Jones SJM
    JAMA Netw Open; 2019 Apr; 2(4):e192597. PubMed ID: 31026023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Histogenetic Analysis Reveals
    Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
    J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
    Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving lung cancer risk stratification leveraging whole transcriptome RNA sequencing and machine learning across multiple cohorts.
    Choi Y; Qu J; Wu S; Hao Y; Zhang J; Ning J; Yang X; Lofaro L; Pankratz DG; Babiarz J; Walsh PS; Billatos E; Lenburg ME; Kennedy GC; McAuliffe J; Huang J
    BMC Med Genomics; 2020 Oct; 13(Suppl 10):151. PubMed ID: 33087128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies.
    Tessier-Cloutier B; Grewal JK; Jones MR; Pleasance E; Shen Y; Cai E; Dunham C; Hoang L; Horst B; Huntsman DG; Ionescu D; Karnezis AN; Lee AF; Lee CH; Lee TH; Twa DD; Mungall AJ; Mungall K; Naso JR; Ng T; Schaeffer DF; Sheffield BS; Skinnider B; Smith T; Williamson L; Zhong E; Regier DA; Laskin J; Marra MA; Gilks CB; Jones SJ; Yip S
    J Pathol Clin Res; 2022 Jul; 8(4):395-407. PubMed ID: 35257510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data.
    Bagante F; Spolverato G; Ruzzenente A; Luchini C; Tsilimigras DI; Campagnaro T; Conci S; Corbo V; Scarpa A; Guglielmi A; Pawlik TM
    Eur J Cancer; 2021 May; 148():348-358. PubMed ID: 33774439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen.
    Marquard AM; Birkbak NJ; Thomas CE; Favero F; Krzystanek M; Lefebvre C; Ferté C; Jamal-Hanjani M; Wilson GA; Shafi S; Swanton C; André F; Szallasi Z; Eklund AC
    BMC Med Genomics; 2015 Oct; 8():58. PubMed ID: 26429708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CancerNet: a unified deep learning network for pan-cancer diagnostics.
    Gore S; Azad RK
    BMC Bioinformatics; 2022 Jun; 23(1):229. PubMed ID: 35698059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convolutional neural network models for cancer type prediction based on gene expression.
    Mostavi M; Chiu YC; Huang Y; Chen Y
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):44. PubMed ID: 32241303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.
    Törrönen K; Soini Y; Pääkkö P; Parkkinen J; Sironen R; Rilla K
    Histol Histopathol; 2016 Oct; 31(10):1113-22. PubMed ID: 26912058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
    De Rienzo A; Richards WG; Yeap BY; Coleman MH; Sugarbaker PE; Chirieac LR; Wang YE; Quackenbush J; Jensen RV; Bueno R
    Clin Cancer Res; 2013 May; 19(9):2493-502. PubMed ID: 23493352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.